Advancing early cancer screening and detection.

Identifying cancer and other diseases with high sensitivity, specificity, and accuracy.

Anpac Bio uses proprietary, multi-level multi-parameter screening algorithms to identify cancer.

Analyzing blood samples with CDA technology.

26 Cancer types detected

Detects the risks of 26 different types of cancer—often identifying cancer at its early stages: Covering 80% of cancer incidences in China from 2013 to 2018

121 Patents granted

121 issued patents granted to date around its Cancer Differentiation Analysis (“CDA”) technology.

Cost Savings

Significant cost advantages compared to other screening technologies

Market Potential

In addition to cancer screening and risk detection, Anpac Bio’s CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.

Results speak. Take a look at our research study results to date.

Anpac Bio scientists have published and presented verified research studies at the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit on Biomedical Sciences, among others.

Continued Clinical research is at the core of our progress.

Shared philosophies, cultural alignment, and an open exchange of ideas unifies our efforts as we continue to pioneer the “liquid biopsy” market, proving theory with evidence.

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article
©2019 Anpac Bio-Medical Science Co., Ltd.
;